The Pilot study is designed to evaluate the overall safety and feasibility of a strategy based on subcutaneous delivery of furosemide. It will be used to inform the subsequent evaluation phase of the study (separate protocol). The primary objective of the study is to determine if a strategy of a novel subcutaneous delivery of furosemide is safe and feasible in patients with acute heart failure.
Full Title of Study: “Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Pilot Study”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: November 7, 2017
Multi-center, open-label, pilot study conducted in 2 phases. Each phase will enroll 20 subjects that will be used to inform the study design of the SUBQ-HF Study (approximately 300 evaluable patients randomized to either usual inpatient care or early discharge with home subcutaneous furosemide for 1-7 days). Inpatient Pilot Phase: Eligible in-patients will be approached for participation. Subjects who consent for participation will be treated with subcutaneous furosemide for 48 hours, during which they will remain in the hospital. This will be primarily a safety and feasibility assessment. There will be no formal hypothesis tested, and statistical analysis will be descriptive in nature. Outpatient Pilot Phase: Eligible in-patients who are nearing discharge will be approached for participation. Subjects who consent for participation will be instructed on use of device, discharged to home and treated at home with subcutaneous furosemide for 1-7 days. This will be primarily a safety and feasibility assessment. There will be no formal hypothesis tested, and statistical analysis will be descriptive in nature.
- Drug: Furosemide
- subcutaneous furosemide delivered via subcutaneous pump
Arms, Groups and Cohorts
- Experimental: Active
- All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
Clinical Trial Outcome Measures
- Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events
- Time Frame: 14 days
- The analysis of data from the Pilot Phase will be primarily descriptive in nature and there will be no formal hypothesis testing. Number of patients with events will be reported.
Participating in This Clinical Trial
1. Age >18 years 2. Willingness and ability to provide informed consent 3. Hospitalization for acute heart failure (AHF) with at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography, Brain Natriuretic Peptide > 250 ng/mL or N-terminal pro-brain natriuretic peptide (NTproBNP) > 1000 ng/mL) of congestion 4. Persistent congestion despite at least 18 hours of intravenous (IV) therapy, defined by the presence of at least 2 or more of the following at the time of consent:
- Peripheral edema – Rales – Elevated jugular venous pressure (JVP) – Ascites – BNP > 250 ng/mL or NTproBNP > 1000 ng/mL 5. Total anticipated daily IV furosemide dose (at time of screening) >80-200 mg (or equivalent)/day 6. Anticipated need for at least 24 more hours of parenteral diuretic therapy - Exclusion Criteria:
1. Severe renal dysfunction (Estimated Glomerular Filtration Rate (eGFR)< 30 ml/min/1.73m2) 2. Requirement for inotropes (other than digoxin) or mechanical support during hospitalization 3. Clinically significant electrical instability during hospitalization 4. Ongoing need for other intravenous therapies beyond diuretics (vasodilators, antibiotics, etc.) 5. Anticipated need for ongoing parenteral electrolyte repletion 6. Planned discharge to location other than home (e.g, hospice, skilled nursing facility, etc.) 7. Anticipated cardiac transplantation or left ventricular assist device within the next 30 days 8. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade 9. Known or anticipated pregnancy in the next 30 days Prior use of subcutaneous furosemide pump or current use of any subcutaneous pump, on-body infusion devices or patients who give regimented injections at the intended site of the furosemide infusion device 10. Other psychosocial or physical barriers to following the protocol and using a subcutaneous pump device outside the hospital setting 11. Unable to accurately measure urine output 12. Known allergy to furosemide 13. Known sensitivity or allergy to medical adhesive tape
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Adrian Hernandez
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Adrian Hernandez, HFN Coordinating Center PI – Duke University
- Overall Official(s)
- Adrian Hernandez, MD, Principal Investigator, Duke University
- Eugene Braunwald, MD, Study Chair, Harvard University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.